Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
Malagola
Michele
M
Martinelli
Giovanni
G
Rondoni
Michela
M
Paolini
Stefania
S
Gaitani
Stavrula
S
Arpinati
Mario
M
Piccaluga
Pier Paolo
PP
Amabile
Marilina
M
Basi
Constanza
C
Ottaviani
Emanuela
E
Candoni
Anna
A
Gottardi
Enrico
E
Cilloni
Daniela
D
Bocchia
Monica
M
Saglio
Giuseppe
G
Lauria
Francesco
F
Fanin
Renato
R
Visani
Giuseppe
G
Marrè
Maria Carla
MC
Maderna
Michela
M
Rancati
Francesca
F
Vinaccia
Vincenza
V
Russo
Domenico
D
Baccarani
Michele
M
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit